This prospective, parallel-group, randomized, double-blind, multicenter study compared the efficacy and safety of FV-100 with valacyclovir for reducing pain associated with acute herpes zoster (HZ). Patients, ≥50 years of age, diagnosed with HZ within 72 h of lesion appearance who had HZ-associated pain, were randomized 1:1:1 to a 7-day course of either FV-100 200 mg QD (n = 117), FV-100 400 mg QD (n = 116), or valacyclovir 1000 mg TID (n =117). Efficacy was evaluated on the basis of the burden of illness (BOI; Zoster Brief Pain Inventory scores); incidence and duration of clinically significant pain (CSP); pain scores; incidence and severity of post-herpetic neuralgia (PHN); and times to full lesion crusting and to lesion healing. Safety was evaluated on the basis of adverse event (AE)/SAE profiles, changes in laboratory and vital signs values, and results of electrocardiograms. The burden of illness scores for pain through 30 days were 114.5, 110.3, and 118.0 for FV-100 200 mg, FV-100 400 mg, and valacyclovir 3000 mg, respectively. The incidences of PHN at 90 days for FV-100 200 mg, FV-100 400 mg, and valacyclovir 3000 mg were 17.8%, 12.4%, and 20.2%, respectively. Adverse event and SAE profiles of the two FV-100 and the valacyclovir groups were similar and no untoward signals or trends were evident. These results demonstrate a potential for FV-100 as an antiviral for the treatment of shingles that could both reduce the pain burden of the acute episode and reduce the incidence of PHN compared with available treatments. K E Y W O R D S antiviral agents, herpes simplex virus, herpes virus, reinfection 1 | BACKGROUND Varicella zoster virus (VZV) is a human alpha herpes virus, which causes varicella (chicken pox) and herpes zoster (HZ). Approximately one out of three people in the United States aged 60 years or older will develop shingles. 1
the US) of the at-risk population does not receive the vaccine. 13 About half of people, 60 years of age or older who have had the shingles vaccine, fail to respond (eg, primary failure meaning they failed to seroconvert after vaccination) and may go on to develop HZ. 12, 14 In addition, the efficacy of the vaccine has been shown to decline over time (eg, secondary vaccine failure). 15, 16 Several drugs, including acyclovir, valacyclovir, and famciclovir, have demonstrated minimal efficacy in terms of pain control for patients with HZ. 17 Additionally, a significant proportion of these patients (∼20-40% and sometimes more) go on to develop PHN. 3, 18 These drugs require multiple doses of medication each day. [19] [20] [21] Furthermore, doses of these antiviral agents must be modified for patients with renal impairment. It is evident that a drug with greater antiviral activity, better pain relief, and a more simplified dosing regimen represents a significant unmet medical need. Brivudine is also available in some countries for treating shingles. 22 FV-100 is a prodrug for the bicyclic nucleoside analogue CF-1743. 23 CF-1743 demonstrates high potency against clinical VZV isolates (EC 50 ∼440 pM). The inhibitory activity of FV-100 and CF-1743 is highly specific for VZV. Renal clearance for FV-100 and CF-1743 was demonstrated to be low for all doses tested (100, 200, 400, and 800 mg QD), indicating that renal elimination is not likely to be an important pathway for either compound. In light of these results, a Phase 2 clinical trial was undertaken in patients with HZ in order to evaluate the efficacy of once-daily (QD) FV-100 at both the 200 mg and 400 mg doses, compared with valacyclovir 3000 mg administered three times daily (1000 mg TID) in reducing the acute herpes zoster burden of illness (BOI) and reducing the incidence of PHN.
| STUDY DESIGN
This was a multicenter, randomized, parallel-group, comparative study of FV-100 versus valacyclovir in patients with HZ conducted at 90 centers in the United States between May 2009 and December 2010. Patients who presented within 72 h of zoster rash and met all eligibility criteria were randomized 1:1:1 to one of three treatment groups: 1) FV-100 200 mg QD; 2) FV-100 400 mg QD; or 3) valacyclovir 3000 mg (1000 mg TID). Patients were centrally randomized by an interactive web response system and stratified by 1) age category (<65 vs. ≥65); and 2) Visit 1/Day 1 ZBPI worst pain in the last 24 h score (<6 vs. >6). Sites were blinded to all ZBPI subset pain scores throughout the study.
The primary endpoint was the reduction in the mean BOI-30 AUC, a standardized score measuring the overall severity of pain experienced by study subjects during the 30 days after the first dose of study drug (see section 2.3). A sample size of at least 333 patients (111 per arm) was calculated to achieve 80% power to detect a 25% reduction in the mean BOI-30 AUC in the FV-100 treated group compared to the valacyclovir-treated group. Estimates of BOI-30 AUC and SD (constant SD across treatment arms) were extrapolated from the Zostavax Shingles Prevention Study and the ZBPI validation study. 21, 24, 25 All eligible patients were treated for 7 days and followed through Day 30. Patients who continued to have HZ-associated pain or whose rashes had not healed by Day 30 were followed through Day 90 or until their rash healed and they had two documented Zoster Brief Pain Inventory (ZBPI) worst pain scores of 0, whichever occurred first.
The study was approved by a central institutional review board (IRB) or local IRBs and conducted in accordance with the International Committee on Harmonization Guidelines for Good Clinical Practice and the 1964 Declaration of Helsinki. 26, 27 This study was registered on clinicaltrials.gov (NCT00900783).
| Patients
Patients were ≥50 years of age, had a clinical diagnosis of HZ as evidenced by a unilateral dermatomal rash present for ≤72 h, and had zoster-related pain as defined by a ZBPI worst pain score >0.
Patients were excluded for multidermatomal, disseminated, or ophthalmic HZ; impaired renal function, immunosuppression;
gastrointestinal dysfunction that could interfere with absorption; chronic pain requiring narcotic analgesics; the use of tricyclic antidepressants, systemic or cutaneous antivirals within 30 days of enrollment, or CYP3A4-inhibiting protease inhibitors, and strong CYP3A4 inhibitors and inducers. were recorded throughout the study. The numbers of capsules and caplets remaining in the study drug wallet on Day 7 were recorded to assess study medication compliance.
| Assessments

| Endpoints
The primary efficacy measure was the reduction of the HZ BOI over 30 days (measured by BOI-30 AUC ). This endpoint was derived from a patient's reported score on a scale from 0 (no pain) to 10 (pain as bad as you can imagine) on question #3 of the ZBPI, which rated a patient's "worst pain in the last 24 h" over the period from Study Day 1 to Study Day 30. Secondary endpoints included the following: HZ BOI scores through 14 days (BOI-14 AUC ) and 90 days (BOI-90 AUC ), incidence and severity of PHN at 90 days after lesion appearance, time to full lesion crusting and lesion healing, use of concomitant pain medication, and zoster pain-related interference in functional categories as assessed by the ZBPI. CSP was defined as a worst pain score >3 as reported on the ZBPI. Safety was assessed using adverse events (AEs), clinical laboratory testing, vital signs, electrocardiograms, and physical exams.
DNA samples were extracted from lesion swabs on days 1 and 7 and analyzed for phenotypic resistance.
The main efficacy analyses were conducted on a modified intentto-treat population (MITT2), defined as all randomized patients who received at least one dose of study drug.
The burden of illness (BOI-AUC) was calculated as follows: 
| Statistical analyses
The The safety population consisted of all randomized patients who received at least one dose of study drug. All safety analyses were descriptive.
| RESULTS
Of the 466 patients screened, 350 were randomized and received at least one dose of study drug ( Fig. 1 ). Some patients (34) were excluded due to their low creatinine clearance (<50 mL/min/1.73 m 2 ), leaving 329 for the modified ITT efficacy analysis. The mean age of patients was 64.6 years. Most patients (65%) were women. All other baseline demographic characteristics were similar between groups ( Table 1) .
Approximately 15% of patients overall had a history of HZ. The mean number of prior occurrences was 1.5 for the study (range 1-5). Fewer than 5% of the patients had received the HZ vaccine.
Most patients (78.4%) reported baseline prodromal pain. At onset of treatment the mean (SD) worst pain score was 6.3 (2.5). However, 30% of baseline average pain scores were rated at three or below by patients, limiting the ability of this study to analyze the impact of the treatment on pain.
| Burden of illness
The LS mean BOI-30 AUC values (SD) for FV-100 200 mg, FV-100 400 mg, and valacyclovir 3000 mg were 114.5 (6.2), 110.3 (6.1), and 118.0 (6.3), respectively ( Table 2 ). This Phase 2 study was not powered to show differences in the BOI-30 AUC between groups of less than 25%, however, the results suggested a dose response for FV-100.
Notably, the differences between the mean BOIs for FV-400 mg and valacyclovir 3000 mg became more pronounced with time. 
| Post-herpetic neuralgia
| Pain endpoints
Trends in faster resolution of pain in both the FV-100 groups compared to valacyclovir were noted for other a priori endpoints, with potential TYRING ET AL.
FIGURE 1
Study flow chart. The chart shows the relationships between all analysis populations. All patients were included in both the safety and ITT population. The differences in Ns of the treatment groups between the safety and ITT population are because of errors in dispensing for two patients that received a treatment different from their randomized assignment. The ITT population consisted of all randomized patients who received at least one dose of study drug. The MITT1 population consisted of all randomized patients who receive at least one dose of study drug except for patients whose lesion swabs were positive by PCR for HSV and negative by PCR for VZV or who had a calculated creatinine clearance <50 mL/min/1.73m 2 . The MITT2 population consisted of all randomized patients who received at least one dose of study drug except for patients whose lesions swabs were positive by PCR for HSV and negative by PCR for VZV. The per-protocol population consisted of all patients from the ITT population who had a lesion swab positive for VZV, were followed for at least 30 days, received at least 6 of 7 days of study drug, and had no major protocol violations. HSV, herpes simplex virus; ITT, intent-to-treat; MITT, modified intent-to-treat; PCR, polymerase chain reaction; QD, once daily; TID, three times daily; VZV, Varicella zoster virus dose effects observed between the two groups ( Table 4) Race and ethnicity (whether or not Hispanic/Latino) were collected as separate variables. All subjects for whom Hispanic/Latino ethnicity was recorded were of Caucasian race except one subject who was of mixed race. 
| Post-hoc analyses
Post hoc analyses were conducted to gain more insight into the effect of FV-100 on subacute and chronic pain. BOI-14-90 AUC and BOI-30-90 AUC both showed that patients on FV-100 generally had lower burdens of illness than those on valacyclovir. A dose response was suggested for BOI-14-90 AUC and a trend toward better pain management from week 2 onward was observed for FV-100 400 mg. These results corroborated the prospective observations.
These post hoc analyses results are shown in the supplemental material.
| Virology
The virology results are described in the supplemental material. 
| Safety
Approximately 48% of the total population experienced an AE (FV-100 200 mg = 47%, FV-100 400 mg = 54%, and valacyclovir = 42%) (Table 5 ). Overall, most AEs were mild in severity, and there were no 
| DISCUSSION
Postherpetic neuralgia is known to cause the largest burden of illness for patients with HZ. 8, 9 A significant proportion of patients with HZ develop PHN despite treatment with the current antiviral agents. 6, 7 These antivirals require dosing regimens (3-5 times daily) that must be modified for patients with renal impairment. [19] [20] [21] The current medications used to treat the pain associated with PHN fall short in terms of relief for many patients. 8 In addition pain medications are only palliative and do not provide a cure for HZ.
Hence, a drug with greater antiviral activity, the ability to prevent PHN, better pain relief, and a more simplified dosing regimen is needed.
Although there was no statistically significant difference among the treatment groups for the primary endpoint of BOI-30 AUC , a difference between the FV-100 400 mg and valacyclovir groups emerged in the 90-day data (a 14% reduction), suggesting a potential We acknowledge that the assessment of pain is a relatively subjective measure. However, the ZBPI, 18 and is a sensitive and reliable measure of the impact of HZ and PHN on patients' daily lives. 25 In addition, the use of worst pain score of ≥3 in the definition of PHN has been validated as part of the development of the ZBPI 25 In spite of the availability of antiviral drugs approved for the treatment of HZ, and the availability of the HZ vaccine, up to 40% of all patients with HZ will go on to develop PHN. 6, 7, 12, [31] [32] [33] Pain associated with PHN is often refractory to treatment, and symptomatic relief is obtained in fewer than half of PHN sufferers despite the frequent use of multiple drugs for pain control. [34] [35] [36] [37] While the majority of patients experience complete resolution of their pain by one year, long-term studies indicate that PHN may persist indefinitely. 36, 38, 39 Taken as a whole, these findings support the conclusion that PHN represents a significant unmet medical need.
Based on the analyses in this Phase 2 study, a multicenter, randomized, double-blind, parallel-group Phase 3 study has been designed, which is powered to assess the safety and efficacy of 400 mg FV-100 dosed either once or twice daily. The study measures the effect on HZ-associated subacute and chronic pain, compared with TID valacyclovir 1000 mg (3000 mg daily dose). This Phase 3 study is designed to confirm that FV-100 will address the need for a more effective medication to prevent and treat HZ.
In conclusion, the comprehensive results of the burden of illness, Leading to study drug discontinuation 0 1 (0.9) 1 (0.9) 2 (0.6) n, number of subjects reporting at least one adverse event; (%), percentage of subjects among treatment group (N).
